<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415116</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-7216</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-7216</secondary_id>
    <nct_id>NCT00415116</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of Three-Weekly Docetaxel, Carboplatin and Oral CC-5013 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lenalidomide may stop the growth of solid tumors by blocking blood flow to the&#xD;
      tumor. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving lenalidomide together with docetaxel and carboplatin may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when&#xD;
      given together with docetaxel and carboplatin in treating patients with advanced solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of lenalidomide when administered with docetaxel&#xD;
           and carboplatin in patients with advanced solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the clinical activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of lenalidomide.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour followed by carboplatin IV on day 1. Patients also&#xD;
      receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for up to&#xD;
      6 courses in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      stable or responding disease after completion of 6 courses of treatment may continue&#xD;
      lenalidomide alone once daily on days 1-14. Patients whose disease is stable or responding&#xD;
      after completing 2 or 4 courses and who are unable to tolerate further chemotherapy may&#xD;
      continue lenalidomide alone once daily on days 1-14, at the investigator's discretion.&#xD;
      Treatment with lenalidomide repeats every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of lenalidomide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. An additional 6-8 patients are treated at&#xD;
      the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of lenalidomide</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity of lenalidomide</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical activity</measure>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven solid tumor&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Refractory to standard treatment&#xD;
&#xD;
          -  No prior failure of a docetaxel and carboplatin regimen except in the adjuvant setting&#xD;
&#xD;
          -  History of brain disease allowed, provided the following criteria are met:&#xD;
&#xD;
               -  Brain disease previously treated with radiotherapy or surgery&#xD;
&#xD;
               -  Asymptomatic with no active brain disease, as documented by CT scan or MRI, for&#xD;
                  at least 3 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if hepatic metastases&#xD;
             are present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would preclude giving informed consent, expose the patient to unacceptable risk, or&#xD;
             affect the interpretation of study data&#xD;
&#xD;
          -  No known hypersensitivity to thalidomide&#xD;
&#xD;
          -  No history of erythema nodosum, characterized by a desquamating rash, while taking&#xD;
             thalidomide or similar drugs&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No known hypersensitivity or intolerance to taxanes&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No known infectious hepatitis, types A, B, or C&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 28 days since prior cancer therapy, including radiotherapy, biologic therapy,&#xD;
             hormonal therapy, chemotherapy, or surgery&#xD;
&#xD;
          -  At least 28 days since any other prior investigational drug or therapy&#xD;
&#xD;
          -  No prior lenalidomide&#xD;
&#xD;
          -  No other concurrent chemotherapy or biologic therapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No concurrent use of any other anticancer agents or treatments&#xD;
&#xD;
          -  No prophylactic granulocyte colony-stimulating factors (G-CSF) during the first course&#xD;
             of study treatment&#xD;
&#xD;
          -  No concurrent prophylactic antibiotics&#xD;
&#xD;
          -  No concurrent treatment with the following medications:&#xD;
&#xD;
               -  Systemic corticosteroids (except as prophylaxis for docetaxel administration)&#xD;
&#xD;
               -  Estrogens&#xD;
&#xD;
               -  Azoles&#xD;
&#xD;
               -  Macrolides&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek M. Mekhail, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tarek Mekhail</name_title>
    <organization>Cleveland Clinic Taussing Cancer Institute</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

